| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
GB:GSK
GlaxoSmithKline
|
Oct 29, 2026 | HOLD |
Hold
+5.2% avg upside
26 analysts
|
$1940.00
4.66% Upside
|
+5.4% | Β· |
|
CH:NOVN
Novartis AG
|
Oct 28, 2026 | HOLD |
Buy
-15.0% avg upside
32 analysts
|
$130.00
2.87% Downside
|
+2.6% | Β· |
|
DE:SRT3
Sartorius
|
Oct 23, 2026 | BUY |
Strong Buy
-0.2% avg upside
19 analysts
|
$300.00
2.84% Upside
|
+0.4% | Β· |
|
CH:ROP
Roche Holding AG
|
Oct 23, 2026 | BUY |
Buy
-12.1% avg upside
24 analysts
|
$376.00
6.80% Downside
|
+3.2% | Β· |
|
DE:MRK
Merck KGaA
|
Oct 15, 2026 | HOLD |
Buy
-7.2% avg upside
34 analysts
|
$150.00
0.90% Downside
|
+3.7% | Β· |
|
DE:BAYN
Bayer
|
Oct 15, 2026 | BUY |
Strong Buy
+8.7% avg upside
31 analysts
|
$62.00
23.47% Upside
|
+27.1% | Β· |
|
GB:0QIU
Novo Nordisk
|
Oct 15, 2026 | HOLD |
Hold
+52.9% avg upside
29 analysts
|
$332.00
24.79% Upside
|
Β· | Β· |
|
FR:DIM
Sartorius Stedim Biotech
|
Oct 15, 2026 | BUY |
Strong Buy
+19.8% avg upside
12 analysts
|
$260.00
16.37% Upside
|
+3.8% | Β· |
|
FR:SAN
Sanofi
|
Oct 15, 2026 | HOLD |
Buy
+21.3% avg upside
30 analysts
|
$78.00
2.12% Downside
|
+21.8% | Β· |
|
CH:GALD
Galderma Group AG
|
Sep 10, 2026 | BUY |
Strong Buy
-0.1% avg upside
12 analysts
|
$200.00
3.78% Upside
|
+23.5% | Β· |
|
GB:AZN
AstraZeneca
|
Aug 04, 2026 | BUY |
Strong Buy
+7.8% avg upside
28 analysts
|
$17600.00
26.11% Upside
|
+16.6% | Β· |
|
MRK
Merck & Company
|
Nov 01, 2024 | BUY |
Strong Buy
-3.5% avg upside
44 analysts
|
$125.00
16.49% Downside
|
-12.5% | Β· |
|
CH:LONN
Lonza Group Ltd
|
Jan 27, 2022 | BUY |
Strong Buy
+1.1% avg upside
21 analysts
|
$750.00
16.45% Upside
|
-15.1% | Β· |
|
FR:IPN
Ipsen
|
Feb 11, 2020 | HOLD |
Hold
-20.5% avg upside
17 analysts
|
$72.00
54.41% Downside
|
+7.8% | Β· |
|
NVO
Novo Nordisk
|
Nov 02, 2018 | HOLD |
Buy
+188.3% avg upside
26 analysts
|
$310.00
674.99% Upside
|
+32.3% | Β· |
|
NVS
Novartis
|
Jul 05, 2017 | SELL |
Hold
-16.0% avg upside
24 analysts
|
β | +4.0% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.